Slimane Zerdoud
Overview
Explore the profile of Slimane Zerdoud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leboulleux S, Bournaud C, Chougnet C, Lamartina L, Zerdoud S, Do Cao C, et al.
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):38-46.
PMID: 39586309
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of...
2.
Latge A, Krim M, Vija L, Ysebaert L, Zerdoud S
Clin Nucl Med
. 2024 Feb;
49(4):340-341.
PMID: 38377372
A 57-year-old woman with history of chronic lymphocytic leukemia was referred to our center for adjuvant 131 I therapy following complete thyroidectomy for differentiated thyroid cancer. Posttherapeutic scintigraphy revealed atypical...
3.
Jannin A, Giudici F, De La Fouchardiere C, Al Ghuzlan A, Wassermann J, Chougnet C, et al.
Thyroid
. 2023 Oct;
33(10):1190-1200.
PMID: 37855745
Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the...
4.
Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, et al.
Trials
. 2023 Jul;
24(1):452.
PMID: 37434205
No abstract available.
5.
Glemarec G, Lacaze J, Cabarrou B, Aziza R, Jouve E, Zerdoud S, et al.
Breast
. 2023 May;
69:424-427.
PMID: 37172498
No abstract available.
6.
Hartl D, Godbert Y, Carrat X, Bardet S, Lasne-Cardon A, Vera P, et al.
Trials
. 2023 Apr;
24(1):298.
PMID: 37118818
Background: Prophylactic central neck dissection in clinically low-risk cT1bT2N0 papillary thyroid carcinoma is controversial, due to a large number of conflicting retrospective studies, some showing an advantage in terms of...
7.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, et al.
Clin Cancer Res
. 2023 Apr;
29(13):2401-2409.
PMID: 37074727
Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation. Patients And Methods: A...
8.
Glemarec G, Lacaze J, Cabarrou B, Aziza R, Jouve E, Zerdoud S, et al.
Breast
. 2023 Jan;
67:102-109.
PMID: 36709639
Purpose: Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support this strategy. We evaluated the addition of LAT...
9.
Leboulleux S, Bournaud C, Chougnet C, Zerdoud S, Al Ghuzlan A, Catargi B, et al.
N Engl J Med
. 2022 Mar;
386(10):923-932.
PMID: 35263518
Background: In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, the postoperative administration of radioiodine (iodine-131) is controversial in the absence of demonstrated benefits. Methods: In this prospective, randomized, phase...
10.
Forrer F, Fischer G, Maas O, Giovanella L, Hoffmann M, Iakovou I, et al.
Oncology
. 2021 Nov;
100(2):74-81.
PMID: 34788758
The role of radioiodine therapy (RIT) (used as ablation therapy or adjuvant therapy) following total thyroidectomy for differentiated thyroid cancer (DTC) changed. Major revisions of the American Thyroid Association (ATA)...